Aprecia Patent-Cliff Exposure & CMS Drug Spending Portfolio

Aprecia (US): 1 reconciled FDA prescription therapies, $3.0M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2034-01-01
2024 CMS Total Public Spend$3.0M
2024 Medicare Part D Spend$1.5M
2024 Medicaid Spend$1.6M
California HCAI SB 17 Filings4 WAC filings (max 16.1% 2-yr change)